Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

COR Therapeutics, Inc. Appoints James N. Topper, M.D., Ph.D., Vice President, Biology.


SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BW HealthWire)--Sept. 22, 1999--

COR Therapeutics, Inc. (Nasdaq:CORR CORR

Used on the consolidated tape to indicate a correction in a reported transaction : CORR.LAST.GY 50 WAS 51.
) announced today that James N. Topper, M.D., Ph.D., has joined the Company as Vice President, Biology. In this newly created position, Dr. Topper will have overall responsibility for the biological research responsibilities at COR and will report directly to Charles J. Homcy, Executive Vice President, Research and Development.

Prior to joining COR, Dr. Topper was an Assistant Professor of Medicine at Stanford University School of Medicine Stanford University School of Medicine is affiliated with Stanford University and is located at Stanford University Medical Center in Stanford, California, adjacent to Palo Alto and Menlo Park.  and an attending cardiologist at Stanford Hospital. Dr. Topper received his M.D. and Ph.D. degrees from Stanford University School of Medicine and completed a residency in Internal Medicine and fellowships in Cardiology and Vascular Medicine at the Brigham and Women's Hospital Brigham and Women's Hospital (BWH) is a hospital in the Longwood Area of the Boston, Massachusetts neighborhood of Mission Hill. With Massachusetts General Hospital, it is one of the two founding members of Partners HealthCare. . Subsequently, he served on the faculty of Harvard Medical School Harvard Medical School (HMS) is one of the graduate schools of Harvard University. It is a prestigious American medical school located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts.  prior to joining Stanford University.

Dr. Topper's major research interests involve signal transduction and gene expression in the cardiovascular system cardiovascular system: see circulatory system.
cardiovascular system

System of vessels that convey blood to and from tissues throughout the body, bringing nutrients and oxygen and removing wastes and carbon dioxide.
 and the functional genomics of human vascular disease. His area of research complements the ongoing programs at COR.

COR Therapeutics, Inc. is dedicated to the discovery, development and commercialization of novel pharmaceutical products for the treatment and prevention of severe cardiovascular diseases. COR has complementary research and development programs that seek to address critical needs in severe cardiovascular care, including unstable angina, acute myocardial infarction acute myocardial infarction (·kyōōtˑ mī·ō·karˑ·dē· , deep vein thrombosis A blood clot (thrombos) in a vein deep within the muscle, typically in the thigh or calf. It is caused by disease or the lack of activity such as sitting for hours at a computer screen.  and restenosis. For additional information about COR Therapeutics, please visit the Company's Web site at http://www.corr.com.

In addition to the historical information contained herein, this press release may contain forward-looking statements that involve risks and uncertainties. Actual results of the Company's activities may differ significantly from the potential results discussed in such forward-looking statements. Forward-looking statements are based on current expectations and the Company assumes no obligation to update such information. A full discussion of COR Therapeutics' operations and financial condition, and specific factors that could cause the Company's actual performance to differ from current expectations, can be found in the Company's SEC reports, including, but not limited to, the Company's Report on Form 10-Q for the quarter ended June 30, 1999, and Report on Form 10-K for the year ended December 31, 1998.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Sep 22, 1999
Words:360
Previous Article:Retrospettiva Announces Status of Orders From Dress Barn Inc. and TJX Cos. Inc.
Next Article:Oncologist With Terminal Cancer Says He Paid Life Insurance Premiums for Years and has Nothing to Show.
Topics:



Related Articles
SIBIA appoints Dr. Francis Crick to board of directors; joins Nobel Laureate Dr. James Watson in providing guidance to company.
PROCEPT TO DEVELOP THERAPIES FOR TUBERCULOSIS- OTHER IMPORTANT, WIDESPREAD INFECTIOUS DISEASES; High Profile Boston Biotech Investor Group Forms...
Regeneron Promotes Yancopoulos to Chief Scientific Officer; Also Names Valenzuela Vice President.
ARIAD Announces Appointment of Manfred Weigele, Ph.D. As Chief Scientific Officer.
COR Therapeutics, Inc. Announces Management Changes.
COR Announces Over 20 Presentations on INTEGRILIN -eptifibatide- Injection to be Featured at the Upcoming American Heart Association Scientific...
Novel ADP Receptor Cloned by COR Therapeutics, Inc., and UCSF Collaboration, Paper Published in NATURE.
Regeneron Announces Executive Appointments; Yancopoulos Named President, Regeneron Research Laboratories, Chief Scientific Officer, and Executive...
COR Therapeutics Licenses the Rosetta Resolver Gene Expression Data Analysis System.
Biology teaching at Hanover college, 1832-1984.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles